Ceftazidime Pentahydrate(Contain 1 equivalent of Na2CO3 as stabilizer)

• CAT Number: R010010
• CAS Number: 78439-06-2
• Molecular Formula: C22H22N6O7S2 • 5H2O
• Molecular Weight: 636.70
• Purity: ≥95%
• Synonyms: 1-[[(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium Inner Salt Pentahydrate; Biotum; Ceftacidin; Fortam; Fortaz; Fortum; GR 20263; Mo
• Target: Beta-lactamase
• Storage: -20°C
• IUPAC Name: (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;pentahydrate
• InChI: InChI=1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13+;;;;;/t14-,18-;;;;;/m1...../s1
• InChIKey: NMVPEQXCMGEDNH-NLYPMKEPSA-N
• SMILES: CC(C)(C(=O)O)O/N=C(\C1=CSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-].O.O.O.O.O

Ceftazidime Pentahydrate (with 1 equivalent of Na₂CO₃ as a stabilizer)（Cat No.:R010010）is a third-generation cephalosporin antibiotic primarily used for treating severe Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa. The addition of sodium carbonate stabilizes the compound, enhancing its solubility and stability for intravenous or intramuscular administration. Ceftazidime Pentahydrate disrupts bacterial cell wall synthesis, leading to cell death, and is effective in hospital settings for critical infections like septicemia, pneumonia, and meningitis. Its β-lactamase resistance makes it particularly valuable in combating drug-resistant bacterial strains.

Reference

1: Li J, Learoyd M, Qiu F, Zhu L, Edeki T. A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects. Clin Drug Investig. 2015 Dec 9. [Epub ahead of print] PubMed PMID: 26649741.2: Ebihara T, Oshima S, Okita M, Shiina S, Negishi A, Ohara K, Ohshima S, Iwasaki H, Yoneyama A, Kitazumi E, Kobayashi D. Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs. Curr Ther Res Clin Exp. 2014 Nov 18;77:7-13. doi: 10.1016/j.curtheres.2014.09.006. eCollection 2015 Dec. PubMed PMID: 26649076.3: Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA. Exposing a β-lactamase /twist/: the mechanistic basis for the high level of ceftazidime resistance in the C69F variant of the Burkholderia pseudomallei PenI β-lactamase. Antimicrob Agents Chemother. 2015 Nov 23. pii: AAC.02073-15. [Epub ahead of print] PubMed PMID: 26596949.4: Siriwong S, Thumanu K, Hengpratom T, Eumkeb G. Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes. Evid Based Complement Alternat Med. 2015;2015:759459. doi: 10.1155/2015/759459. Epub 2015 Oct 21. PubMed PMID: 26576195; PubMed Central PMCID: PMC4631891.5: Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh- or Lung-Infection. Antimicrob Agents Chemother. 2015 Nov 2. pii: AAC.01269-15. [Epub ahead of print] PubMed PMID: 26525790.6: Das S, Li J, Armstrong J, Learoyd M, Edeki T. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015 Oct;3(5):e00172. doi: 10.1002/prp2.172. Epub 2015 Aug 25. PubMed PMID: 26516584; PubMed Central PMCID: PMC4618643.7: Goh JH, Lee SY, Ooi ST, Lee Soon-U L, Hee KH, Renaud CJ. Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use. Hemodial Int. 2015 Oct 20. doi: 10.1111/hdi.12377. [Epub ahead of print] PubMed PMID: 26486806.8: Dupont H, Gaillot O, Goetgheluck AS, Plassart C, Emond JP, Lecuru M, Gaillard N, Derdouri S, Lemaire B, Girard de Courtilles M, Cattoir V, Mammeri H. Molecular Characterization of Carbapenem-Non-Susceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations. Antimicrob Agents Chemother. 2015 Oct 19. pii: AAC.01559-15. [Epub ahead of print] PubMed PMID: 26482307.9: Kwee F, Walker SA, Elligsen M, Palmay L, Simor A, Daneman N. Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study. Can J Hosp Pharm. 2015 Sep-Oct;68(5):386-94. PubMed PMID: 26478584; PubMed Central PMCID: PMC4605462.10: Collins RD, Tverdek FP, Bruno JJ, Coyle EA. Probable Nonconvulsive Status Epilepticus With the Use of High-Dose Continuous Infusion Ceftazidime. J Pharm Pract. 2015 Oct 16. pii: 0897190015608503. [Epub ahead of print] PubMed PMID: 26475124.11: Mutters NT, Zimmermann S, Kaase M, Mischnik A. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2429-37. doi: 10.1007/s10096-015-2498-3. Epub 2015 Oct 3. PubMed PMID: 26433746.12: Mawal Y, Critchley IA, Riccobene TA, Talley AK. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol. 2015 Nov;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30. PubMed PMID: 26420166.13: Yuan XY, Yu DY, Qu XH, Xiao XQ, Bi B, Sun SB, Chang AY, Zhang QB. Increased resistance rate to ceftazidime among blood culture isolates of ESBL-producing Escherichia coli in a university-affiliated hospital of China. J Antibiot (Tokyo). 2015 Sep 30. doi: 10.1038/ja.2015.100. [Epub ahead of print] PubMed PMID: 26419415.14: Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli. Antimicrob Agents Chemother. 2015 Dec;59(12):7842-6. doi: 10.1128/AAC.02019-15. Epub 2015 Sep 21. PubMed PMID: 26392487.15: Arnold CJ, Ericson J, Cho N, Tian J, Wilson S, Chu VH, Hornik CP, Clark RH, Benjamin DK Jr, Smith PB; Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee. Cefepime and Ceftazidime Safety in Hospitalized Infants. Pediatr Infect Dis J. 2015 Sep;34(9):964-8. doi: 10.1097/INF.0000000000000778. PubMed PMID: 26376308; PubMed Central PMCID: PMC4573537.16: Caravaca-Fontán F, Jiménez-Álvaro S, Marcén-Letosa R, Fernández-Rodríguez A, Rodríguez-Navarro CQ. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation. Nefrologia. 2015;35(4):412-3. doi: 10.1016/j.nefro.2015.01.001. Epub 2015 Jul 22. English, Spanish. PubMed PMID: 26306955.17: Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622. PubMed PMID: 26289307; PubMed Central PMCID: PMC4545577.18: Drexler M, Dwyer T, Kuzyk PR, Kosashvilli Y, Abolghasemian M, Regev GJ, Kadar A, Rutenberg TF, Backstein D. The results of two-stage revision TKA using Ceftazidime-Vancomycin-impregnated cement articulating spacers in Tsukayama Type II periprosthetic joint infections. Knee Surg Sports Traumatol Arthrosc. 2015 Aug 14. [Epub ahead of print] PubMed PMID: 26272061.19: Quandt-Herrera P, Suarez-Jesus J, Yelmo-Cruz S. Antibiomania: Secondary Mania Associated With Ceftazidime. J Clin Psychopharmacol. 2015 Oct;35(5):619-21. doi: 10.1097/JCP.0000000000000380. PubMed PMID: 26270201.20: Soren O, Brinch KS, Patel D, Liu Y, Liu A, Coates A, Hu Y. Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro. Antimicrob Agents Chemother. 2015 Oct;59(10):6233-40. doi: 10.1128/AAC.01245-15. Epub 2015 Jul 27. PubMed PMID: 26248380; PubMed Central PMCID: PMC4576052.